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Abstract
Purpose: Due to spatial uncertainty, patient setup errors are of major concern for radiosurgery of multiple brain metastases (m-bm) when using singleisocenter/multitarget (SIMT) volumetric modulated arc therapy (VMAT) techniques. However, recent clinical outcome studies show high rates of tumor local
control for SIMT-VMAT. In addition to direct cell kill (DCK), another possible
explanation includes the effects of indirect cell kill (ICK) via devascularization for
a single dose of 15 Gy or more and by inducing a radiation immune intratumor
response. This study quantifies the role of indirect cell death in dosimetric errors
as a function of spatial patient setup uncertainty for stereotactic treatments of
multiple lesions.
Material and Methods: Nine complex patients with 61 total tumors (2-16
tumors/patient) were planned using SIMT-VMAT with geometry similar to HyperArc with a 10MV-FFF beam (2400 MU/min).Isocenter was placed at the geometric center of all tumors. Average gross tumor volume (GTV) and planning target
volume (PTV) were 1.1 cc (0.02–11.5) and 1.9 cc (0.11–18.8) with an average
distance to isocenter of 5.4 cm (2.2–8.9). The prescription was 20 Gy to each
PTV. Plans were recalculated with induced clinically observable patient setup
errors [±2 mm, ±2o ] in all six directions. Boolean structures were generated to
calculate the effect of DCK via 20 Gy isodose volume (IDV) and ICK via 15 Gy
IDV minus the 20 Gy IDV. Contributions of each IDV to the PTV coverage were
analyzed along with normal brain toxicity due to the patient setup uncertainty.
Induced uncertainty and minimum dose covering the entire PTV were analyzed
to determine the maximum tolerable patient setup errors to utilize the ICK effect
for radiosurgery of m-bm via SIMT-VMAT.
Results: Patient setup errors of 1.3 mm /1.3◦ in all six directions must be
maintained to achieve PTV coverage of the 15 Gy IDV for ICK. Setup errors
of ±2 mm/2◦ showed clinically unacceptable loss of PTV coverage of 29.4 ±
14.6% even accounting the ICK effect. However, no clinically significant effect
on normal brain dosimetry was observed.
Conclusions: Radiosurgery of m-bm using SIMT-VMAT treatments have
shown positive clinical outcomes even with small residual patient setup errors.
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These clinical outcomes, while largely due to DCK, may also potentially be due
to the ICK. Potential mechanisms, such as devascularization and/or radiationinduced intratumor immune enhancement, should be explored to provide a better understanding of the radiobiological response of stereotactic radiosurgery
of m-bm using a SIMT-VMAT plan.
KEYWORDS
direct/indirect cell kill, multiple brain metastases, setup uncertainties, SIMT-VMAT SRS

1

INTRODUCTION

Due
to
fast
treatment
delivery,
singleisocenter/multitarget (SIMT) volumetric modulated
arc therapy (VMAT) stereotactic radiosurgery (SRS)
has become an increasingly popular treatment modality
in the management of multiple brain metastases (mbm).1–3 Recently, this approach has been adopted and
automated by Varian (Varian Medical Systems, Palo
Alto, CA) in the Eclipse treatment planning system (TPS,
version 15.6) as the HyperArc module, which has generated global clinical interest.4–9 SIMT-VMAT reduces
treatment times while improving patient comfort and
clinic workflow; however, there are concerns with patient
setup uncertainty when treating multiple targets simultaneously. It has been previously demonstrated that
clinically unacceptable dosimetric discrepancies due to
rotational setup errors were present compared to treating each lesion individually.10–19 The most recent simulation study demonstrated that there was a large loss of
target(s) coverage (30% average,but up to 70% for small
lesions) due to both rotational and translational setup
errors while using SIMT-VMAT SRS for m-bm.20 This is
a challenge in lining up all tumors correctly using a single
daily cone-beam CT scans, especially since skull-based
rigid alignment is required. In addition, soft tissue visibility is low inside the brain on low-quality cone-beam CT
images. Targets may slightly move if there is intracranial
edema. Nevertheless, a recent clinical study by Palmer
et al. demonstrated positive clinical outcomes of SIMT
treatments.21 They reviewed 173 patients treated with
one to five brain lesions that underwent single-isocenter
SRS treatments. After an average of 12 months following up interval, very promising 1- and 2-year tumor
local control rates of 99 and 95% were observed.
Other clinical studies have observed similar patient
outcomes demonstrating SIMT-VMAT SRS for m-bm
to be both safe and effective with high rates of tumor
response.22–25
However, the presence of positive clinical outcomes
cannot be fully explained knowing the effects of patient
positioning uncertainties in SIMT-VMAT treatments.Biological modeling, specifically with the widely used linearquadratic (LQ) model could potentially overestimate the
tumor control rate with SRS techniques. This is due to
the LQ cell survival curve bends continuously downward

(without limit) with increases in radiation dose because
of the intrinsic quadratic component in the model.26,29
This suggests that mechanisms in addition to tumor
DNA double-strand breaks and/or chromosomal aberrations must be involved. It is hypothesized that in addition to direct cell kill (DCK), the effect of indirect cell kills
(ICK) could be playing a major role in SRS treatments.
There are three types of indirect cell death to consider: strand breaks by free radicals, antitumor immunologic rejection, and devascularization.27 A majority of
the literature suggests that cell death happened soon
after irradiation, pointing toward devascularization as
the mode of ICK.26–29 For instance, Song et al. performed a study to connect the effects of radiobiological response on SBRT and SRS treatments.29 They
concluded that irradiation of tumors with doses higher
than 15 Gy per fraction causes major vascular damage
accompanied by deterioration of intratumor microenvironment resulting in secondary tumor cell death. Other
studies had similar findings.30–34 Tumor vasculature is
disorganized with weak and fragile cellular walls consisting of thin tumor vessels with irregularly shaped
endothelial cells in only a single layer with large gaps.
These vessels are very susceptible to ionizing radiation,
subjecting tumor vasculature to radiation damage when
exposed to a single high-dose (15 Gy or higher) results
in the inverted “hockey-stick” phenomena.29,32–33 With
this theoretical phenomenon, the bend of the cell survival curve increases, where cell death is increasing at
higher doses of radiation. When considering the effects
of ICK, the local tumor control rates with the presence
of dosimetric discrepancies due to patient setup errors
in SIMT-VMAT treatments have yet to be explored.
Therefore, to provide dosimetric support for the potential contribution of secondary cells death in the treatment of m-bm with SIMT-VMAT, a model has been created to define the relationship between spatial setup
uncertainty and the delivered dose. Given the previous
studies suggesting high levels of vascular damage at
15 Gy, the 15 Gy isodose volume (IDV) around the tumor
was chosen as a threshold dose that best utilizes the
effects of ICK in addition to DCK. As long as the target
receives a minimum dose of 15 Gy or higher, vascular
damage could theoretically influence indirect tumor cell
death. This study attempts to characterize the patient
setup errors that should be maintained in the treatment
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TA B L E 1
Patient no.

Main tumor characteristics of the patients included in this study
No. of
lesions

Avg. distance to
isocenter (cm)

Total GTV (cc)

Total PTV (cc)

Adjacent OAR

I

2

2.2

2.2 ± 0.78

3.70 ± 1.10

Hippocampi

II

3

5.7

0.43 ± 0.78

0.93 ± 0.78

Hippocampi

III

4

6.5

3.90 ± 5.20

6.50 ± 8.30

Hippocampi, Optic apparatus

IV

5

8.9

3.30 ± 3.30

4.90 ± 4.30

Hippocampi

V

6

5.4

1.30 ± 0.72

2.10 ± 1.10

Hippocampi

VI

7

5.0

0.75 ± 0.81

1.40 ± 1.20

Brainstem, Hippocampi

VII

8

4.3

0.51 ± 0.58

1.00 ± 0.93

Brainstem, Hippocampi

VIII

10

5.5

0.39 ± 0.46

0.86 ± 0.46

Hippocampi

IX

16

5.4

0.43 ± 0.63

0.83 ± 1.00

Optic apparatus, Hippocampi, Brainstem

of m-bm via SIMT-VMAT to account for both effects
of DCK and ICK. Although the previous studies have
demonstrated the dosimetric effects of translational and
rotational errors, they did not provide the effect of ICK
in the treatment of m-bm using SIMT-VMAT plans.10–20
Therefore, the relationship between ICK and patient
setup errors was used to define an uncertainty cut-off
value. It is clinically useful to know the allowable setup
uncertainties for multilesion SRS treatments. This may
provide limits on patient setup uncertainty that physicians could consider, providing them some clinical guidance in their SIMT-VMAT treatments for treating m-bm
simultaneously.

2
2.1

MATERIALS AND METHODS
Patient information

Nine complex patients with 2–16 (61 total) brain metastases (all lung primary) were included in this study
approved by our institutional review board. These
patients were previously treated through single-fraction
SRS. High-resolution double contrast MPRAGE MRI
images (Siemens MAGNETOM, 1.5T MRI System, Ferndale, MI) were used for tumor and organs at risk
(OAR) delineation and were coregistered to planning CT
images in the Varian Eclipse TPS. The MPRAGE MRI
images were 512 × 512 pixels with 1-mm slice thickness
and no gap in between slices. The target volumes were
delineated by an experienced radiation oncologist on the
MRI with the gross tumor volumes (GTVs) defined by the
visible tumor. The planning target volumes (PTVs) were
created using a uniform 1.0 mm margin around each
GTV using departmental SRS protocol. The tumor characteristics are summarized in Table 1. The normal brain
was considered all tissue with the GTVs included. Additionally, nearby OAR (hippocampi, brainstem, and optics
apparatus) were contoured for dose reporting. Distance
to isocenter was calculated as the 3D Euclidian distance
from the isocenter and the lesion. The average distance

to isocenter was 5.4 cm (range: 2.2 - 8.9 cm) as shown
in Table 1.

2.2

SIMT-VMAT plans

SIMT-VMAT SRS plans were generated in the Eclipse
TPS for the TrueBeam LINAC (Varian Medical Systems,
Palo Alto, CA) with a 10 MV flattening filter-free (FFF)
beam (2400 MU/min). A HyperArc style, fixed-geometry
was mimicked with three noncoplanar partial arcs and
one full arc with couch positions at 0◦ , 45◦ , 315◦ , and
270◦ . The isocenter position was chosen at the approximate geometric center of all targets. Patient-specific collimator angles were manually assigned to best minimize
island blocking and dose spill outside of the target(s).
The prescription was 20 Gy to each lesion to the 70–
80% isodose line and optimized so that 95% of the target volume receives 100% of the prescription dose. The
dose was calculated using Anisotropic Analytic Algorithm (AAA) (Eclipse, version 15.6) with the smallest calculation grid size of 1.25 mm. Ring structures to each
target, jaw tracking, and normal tissue objective were
used during inverse optimization for dose steering and to
maintain dose fall-off outside the target(s). Hippocampi
were spared following RTOG-0933 protocol’s (equivalent dose to SRS) along with the optics apparatus and
brainstem meeting QUANTEC guidelines.35–37

2.3

Simulated SIMT-VMAT plans

Clinically observable patient setup uncertainties of
±0.5 mm/0.5◦ , ±1 mm/1◦ , and ±2 mm/2◦ in all six
degrees-of - freedom (6 DOF) were systematically simulated by using an in-house registration method. Rotational errors were defined as the pitch (y-z plane), roll
(x-z plane), and yaw (x-y plane) relative to the isocenter position. After the SIMT-VMAT plans were generated,
the image set was duplicated and reregistered to the
original MRI images. This registration was exported from
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F I G U R E 1 Example patient’s SIMT-VMAT plan with 16 lesions and a prescription of 20 Gy to each lesion. The left panel shows the original
plan with no induced setup uncertainties, the middle panel shows a simulated plan with 1 mm/1◦ residual patient setup errors and the right
panel shows another simulated plan with 2 mm/2◦ setup uncertainty in all 6 DOF. The orange contour is the PTV(s), the green isodose line is the
prescription dose (20 Gy), and the yellow isodose line is 15 Gy. The simulation plans show decreasingly less coverage by the 20 Gy isodose line
compared to the original plan, demonstrating the dosimetric effects of setup errors and the contribution of ICK

the Eclipse TPS as a DICOM file and imported into a
MATLAB script (Mathworks Inc., WA, USA). The script
generated a matrix with rotational (Δα, Δβ, Δγ) and translational (Δx, Δy, Δz) values and was applied to the reference frame. A new image registration DICOM file was
generated and then imported back into the Eclipse TPS
with a new transformation matrix applied. The original
plan was then overlaid on to the new transformation and
the dose was recalculated with the only difference being
the isocenter shift.

2.4

Modeling direct versus ICK

This work attempts to model the effects of cell killing
due to both direct and ICK methods. An assumption is
made that for areas of the target receiving the prescription dose, 20 Gy or higher, tumor death is due to primarily
direct cell killing methods, or DNA double strand breaks.
Alternatively, for areas of the target receiving 15 Gy or
higher, it is hypothesized that the tumor cell death is
largely due to the ICK method via devascularization of
the tumor and deteriorating the intratumor microenvironment.This threshold for ICK comes from the literature,as
mentioned previously. Doses above 15 Gy could result in
vasculature damage and, therefore, indirectly killing the
tumor cells.26–33 These assumptions are made to simplify the model,though,realistically,combinations of both
direct and ICK are present.
Both DCK and ICK methods were modeled using
Boolean operators in the contouring module of the
Eclipse TPS. For each PTV, the 20 and 15 Gy IDV were
exported from the original SIMT-VMAT plan and each of
the simulated plan for the corresponding patient setup
errors. Boolean operators were used to determine the
overlap of the 20 Gy IDV and each PTV. This volume
was denoted as the volume of the PTV receiving DCK.
Another Boolean operator was used to find the overlap of the 15 Gy IDV and each PTV minus the 20 Gy

IDV overlap with the target. This volume was signified
as the volume of the tumor that was receiving primarily
ICK effects. The concepts are further illustrated in Figure 1. This is an example of a patient with 16 lesions.
The orange contour is the PTVs, the green isodose line
is the prescription dose (20 Gy), and the yellow isodose
line is the 15 Gy.For the original plan,the PTV is well covered by the prescription dose, therefore, should receive
the greatest effects of DCK. However, the simulated plan
with the setup errors of 1 mm and 1◦ shows a slight
deviation of the 20 Gy isodose line, but the tumor is still
covered entirely by the 15 Gy line (see Figure 1). This
should result in a combination of both direct and ICK
in this patient’s treatment, which could result in a positive local tumor control rate. Furthermore, the simulated
plan with 2 mm/2◦ setup errors has shown the significant loss of target coverage by the 20 Gy isodose line,
but still displays a majority of the PTV coverage by the
15 Gy isodose line. With these large setup errors, the
lesions will have a decreased target coverage, therefore,
lower rate of tumor local control, even when considering
the effects of ICK.

2.5

Data analysis

None of these simulated SRS patients were treated
with the SIMT-VMAT plans. This simulation study sought
to find the maximum tolerable patient setup errors to
fully utilize the effects of both direct and ICK to achieve
acceptable local tumor control in the SIMT setting.
Boolean structures of IDV were created iteratively until
a dose was found to just fully cover the target. This process was repeated for the original SIMT-VMAT plans
and each of the corresponding simulated VMAT plan.
Doses found to cover the target with 15 Gy IDV and
above were deemed acceptable and assumed to generate a positive local tumor control rate via ICK. The roles
of DCK versus ICK were also compared for each tumor.
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These were defined by creating Boolean structures for
both the 15 and 20 Gy IDV as further described in the
previous section. The volumes of these structures were
taken and compared as a percentage of the PTV volume receiving that dose. These values were compared
for the original SIMT-VMAT plans and each of the corresponding simulated VMAT plans with the clinically realistic patient setup errors.
It is also of clinical interest to compare the effect
that patient setup uncertainties have on normal brain
dose and the role it could play in radionecrosis. For this
reason, the normal tissue (brain) complication probability (NTCP) was modeled based on a study by Milano
et al.38 This group pooled published reports of clinical data of radiation-induced brain toxicity after receiving brain SRS treatments (single and multiple fractions).
The data were fitted and a logistic model was used to
create a usable NTCP function given by the following
relation:
1

NTCP =
1+(

Vx50 4𝛾50
Vx

)

where Vx is considered the volume receiving greater
than or equal to a dose of x Gy and Vx50 is the volume
corresponding to 50% risk of radionecrosis with 𝛾50 as a
slope parameter. The values of Vx50 and 𝛾50 were taken
from their NTCP model for brain metastases.38 In addition to changes in doses to normal brain and the maximum dose to OAR due to patient setup errors were also
reported.

3

RESULTS

Figure 2 demonstrates the setup uncertainty limitations
for the target (PTV) to be fully covered by at least 15 Gy
or higher and, therefore, best utilize the effects of ICK
in addition to DCK. The dose covering the target was
taken for the original SIMT-VMAT plans and all the corresponding simulated VMAT plans. The original SIMTVMAT plans were found to fully covered the target by
an average of 19.2 ± 0.3 Gy. As expected, the corresponding simulated plans with an induced setup errors
of 0.5 mm/0.5◦ , 1 mm/1◦ , and 2 mm/2◦ were found to
have the corresponding lower doses by 17.8 ± 0.8 Gy,
15.9 ± 0.9 Gy, and 12.6 ± 1.5 Gy, respectively. These
data were evaluated with a threshold of ICK by 15 Gy
or higher in Figure 2. To fully utilize indirect cell killing
methods, patient setup errors of at least 1.3 mm/1.3◦ in
all 6 DOF must be maintained as shown by the background change of blue to red. Above this threshold of
1.3 mm/1.3◦ in all 6 DOF, ICK could potentially contribute
to the tumor cells death.
The contributions of the DCK versus ICK methods
are explained in Figure 3. The Boolean structure of the

F I G U R E 2 Illustration of the dose to target(s) for the original
SIMT-VMAT plans and the corresponding simulated VMAT plans
with 0.5 mm/0.5◦ , 1 mm/1◦ , and 2 mm/2◦ residual patient setup
errors. The blue line represents the dose that fully covers the target
and the dotted red line represents the 15 Gy ICK threshold. The
section of the plot covered in blue represents the target(s) coverage
that is above the 15 Gy threshold, and the orange is below 15 Gy.
Patient setup errors must be limited to those defined by the blue area

20 Gy IDV and PTV is considered primarily DCK contributions, whereas the Boolean structure of the 15 Gy IDV
and PTV minus the 20 Gy IDV is considered contributions from primarily ICK. For the original plans, the PTV
was covered almost completely by the 20 Gy IDV for
97.97 ± 3.52% and no coverage by the 15 Gy IDV.For the
corresponding simulated VMAT plans of 0.5 mm/0.5◦ ,
1 mm/1◦ , and 2 mm/2◦ of setup errors, the 20 Gy IDV
coverage was 80.0 ± 28.5%, 67.9 ± 21.6%, and 47.6 ±
23.6% and the 15 Gy IDV coverage was 4.2 ± 13.1%,
15.4 ± 10.8%, and 29.4 ± 14.6%, respectively. The contribution of DCK decreases as that of ICK increases,
with 2 mm/2◦ having the worst overall target coverage, but most importantly, adding some ICK contributions. The DCK is somehow compensating for much of
the dosimetric discrepancy up to 1.0 mm/1.0◦ . There is
acceptable target coverage (>15 Gy), providing a better
combined coverage, and therefore, potentially providing
positive outcomes.
It has been observed that patient misalignment errors
have minimal or no effect on NTCP of brain as shown in
Figure 4. For each of the patients, the NTCP was calculated and compared with the whole brain receiving V14
Gy. For a majority of patients, there is not much of an
increase in values of NTCP with any setup uncertainties up to 2 mm and 2◦ in each direction. For instance,
the increase of NTCP of normal brain toxicity at setup
errors of 2 mm and 2◦ in each direction had an absolute
difference of less than 0.4% compared to the original
plan with no setup errors, suggesting minimal brain toxicity risk while still resulting in clinical local tumor control.
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F I G U R E 3 Illustration of the target
coverage by the 15 and 20 Gy isodose lines.
The blue represents the coverage obtained by
20 Gy isodose line, which is assumed to be
primarily responsible for DCK. The red
represents the 15 Gy isodose line or more,
which is assumed to be primarily inducing ICK
in addition to DCK. Without considering setup
uncertainty, the target is nearly fully covered by
the prescription isodose line (20 Gy) and could
receive full effects of DCK. With induced setup
errors, the coverage of the target by the
prescription decreases, but is somewhat
counterbalanced by the effects of ICK by
15 Gy or higher

is not clinically significant for lower brain V14 Gy cases
(see Figure 4).
The dose to OAR fluctuated depending on the distribution and orientation of the lesions to the immediately adjacent organs. Many cases resulted in substantial increases in dose to OAR with increased dose to
hippocampi, brainstem, and optic apparatus up to 3, 2,
and 1 Gy, respectively, due to patient setup errors using
SIMT-VMAT.

4

F I G U R E 4 Comparison of NTCP of whole-brain V14Gy for
original SIMT-VMAT plans and the corresponding simulated VMAT
plans with induced setup uncertainties of 0.5 mm/0.5◦ , 1 mm/1◦ , and
2 mm/2◦ in all 6 DOF. Values of Vx50 and γ50 were obtained from
literature as 45.8 cc and 0.88, respectively.37 The blue points
represent NTCP with no setup uncertainty, the red ± 0.5 mm/0.5◦ , the
purple ±1 mm/1◦ , and the green ± 2 mm/2◦ as a function
whole-brain V14Gy. There is no clinically significant increase in NTCP
due to patient setup errors, however, NTCP of normal brain increases
significantly as a function of V14Gy for those patients with increasing
V14Gy above 30 cc

Based on percent differences in NTCP,it was determined
that brain toxicity was 1.3, 1.5, and 1.7% more likely for
0.5 mm/0.5◦ , 1 mm/1◦ , and 2 mm/2◦ simulated plans.
However, it is apparent that NTCP does increase with
whole-brain V14Gy, but the increase due to setup errors

DISCUSSION

In addition to DCK,the effects of ICK responsible for providing better local tumor control rates for SIMT-VMAT
plan are explored with consideration of dosimetric discrepancies due to patient setup errors. This model may
guide the determination of the setup uncertainty limits
for the treating physicians that could utilize ICK effect
to maintain acceptable tumor coverage in the SIMT setting. This was done by determining the dose levels that
fully cover the target for SIMT-VMAT plans with no setup
uncertainty compared to clinically observable patient
setup errors of 0.5 mm/0.5◦ , 1 mm/1◦ , and 2 mm/2◦
in all 6 DOF. Setup limits of at least 1.3 mm and 1.3◦
or better in all 6 DOF was found as the threshold to
maintain an acceptable target dose while including the
effects of ICK. The amount of contribution of both direct
and ICK was also modeled using Boolean structures, so
that 20 Gy IDV was assumed to be primarily responsible for DCK, while the 15 to 20 Gy IDV was assumed
to be primarily contributing due to ICK. As setup uncertainty increases, the contribution of ICK increases (up
to 15 Gy IDV coverage) and, therefore, tumor cell death
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by devascularization. The apparent dosimetric disparity
from losing target coverage of the prescription dose is
partially mitigated by incorporating the concept of secondary cell kill. In addition, the effects of setup uncertainty on the normal brain were modeled using NTCP. No
clinically significant increase of NTCP of the brain due
to setup errors was observed, while clinically significant
increases in OAR are possible for these setup uncertainties due to the proximity of the organs, therefore, the
planner should pay attention to those OAR.
Treating m-bm with a single-isocenter plan comes
with many challenges, including dosimetric disparities,
due to patient positioning errors.14–20 This presents concerns in terms of local tumor control and unexpected
dosing to the normal brain and other adjacent critical
structures in the brain as described above. The QUANTEC guidelines for normal brain tissue cite a study relating V12Gy to radiation-induced necrosis, where the risk
of NTCP increases from 23% for V12Gy between 0 and
5 cc and 54% for V12Gy at 10 to 15 cc.39–40 It should
be noted that dose to whole brain to a certain dose
level is primarily on treated volume rather than number, shape, or location of lesions.41 Several recent clinical outcome studies have reported positive results of
higher tumor local control rates of SIMT-VMAT treatment that do not align with the presence of these dosimetric disparities.21–25 For instance Alongi et al. used
Varian single-isocenter VMAT in the treatment of 43
patients with m-bm and performed a clinical follow-up
study within 6 months. They observed that 60% of the
patients with partial or complete responses and 40%
with stable disease control, though the medial overall
survival had not yet been reported.22 Other studies have
found similar tumor local control rates for linac-based
brain SRS using single-isocenter plans.21,23–24 These
clinical observations lead to the consideration of how
the radiobiology of single fraction, high-dose SRS could
play an important role in SIMT-VMAT for treating m-bm.
Recently, Sperduto et al. discussed the high control
rates of stereotactic body radiation therapy (SBRT) and
SRS and suggested the concept of ICK.32 They discuss
the roles biological models play in the evaluation of
outcomes in SRS treatments. Their results suggest that
a single dose of 15 Gy or higher correlates with indirect
death of hypoxic cells by modes of devascularization
and potentially radiation-induced immune enhancement. The authors conclude that in addition to DCK,
the secondary cell death by modes of devascularization may be the mechanism of interest that providing
success for SRS/SBRT.Other studies concluding devascularization as a relevant form of secondary cell death
have dated back to the 1950s.42–44 Other means of
secondary cell death must also be considered in addition to devascularization. These treatments have shown
to promote antitumor immunity with the expression of
immune modulation molecules such as immunostimulatory cytokines.45–46 However, literature states that
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for brain metastases treated with SRS alone, antitumor
immunity was not sufficiently enough to strongly correlate to the outcomes of the treatment.47 In addition,
radiation-induced tumor-specific immunity does not
present until 1–2 weeks after high doses of radiation.48
The literature cited in this article supports secondary
cell death occurring 2 to 3 days after 20 Gy irradiation,
suggesting that the ICK via devascularization could
contribute predominantly.28 This literature also cited the
abscopal/bystander affects as an alternative mode of
secondary cell death. Though, it is likely that ICK could
be a combination of all the mentioned mechanisms
above. This must be considered when evaluating dosimetric uncertainties due to setup errors for SIMT-VMAT
treatments. Both direct and ICK could be playing roles
in tumor cells death, resulting in the higher local control
rates reported by the mentioned clinical observations.
This simulation study demonstrated that an acceptable
target dose could be maintained when small setup
uncertainties exist because the target coverage by a
dose of 15 Gy or higher is still maintained and therefore cell death by devascularization. It is, therefore,
suggested that if setup errors cannot be maintained
between 1.3 mm/1.3◦ in all 6 DOF, alternative treatment
methods to m-bm should be used. It is recommended
to use either a dual-isocenter approach or traditional
individual isocenter to each tumor methods instead.49–50
Though this study brings perspective to radiobiological effects that exist when treating m-bm via SIMTVMAT plan,some limitations must be considered.Uncertainty evaluated in this report was only due to patient
setup uncertainty due to using a single-isocenter plan.
Other uncertainties are present such as target delineation errors and partial volume effects for the small
lesions. This could also contribute to the apparent loss
of target(s) coverage by the prescription isodose line
and merits future investigation. Though positive clinical outcomes were evident, there were still inconsistencies between the literature for reported local control
rates. This study is describing single fraction treatments
resume, while the literature supporting positive local
control range from single to five fractions with a variable
number of patients receiving WBRT or surgical resection in addition to SRS treatments. They also use larger
margins of 2–3 mm around the GTV, which could be
accounting for some levels of setup uncertainty, though
the effect on the normal brain is not mentioned.21–22
These high local control rates are still useful in describing the ICK effects that could be taking place with high
dose per fraction treatments, even with patient setup
errors were evident, although cannot be predictive for all
patient cohorts. As mentioned previously, an assumption
is made in this study that the 15 Gy or higher IDV is a
parameter of choice to describe the effect of ICK. However, there are some studies suggesting a single dose
of 10–12 Gy as a threshold for ICK.28–30 Moreover, it is
actually a combination of both ICK and DCK methods
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that take place between 15 and 20 Gy, though for simplification, just ICK is considered. Even though, the cutoff value of 15 Gy was approximated for ICK, it would
depend on tumor size, tumor type, and its radiosensitivity as well as immunologic effects. This is a major
assumption that must be considered. This study is also
limited by the TPS resolution limits when considering
the tumor size of this patient cohort. These in combination will cause rounding of errors on IDV and Boolean
structures, meaning some results for very small tumors
will not be as accurate as those of larger tumors. Lastly,
the LQ model is not an adequate representation of a
dose-response relationship for single high dose fraction
SRS treatments, and though work has been done to create a relevant model, there is not currently a definite
solution.51 Though 15 Gy is a potential parameter to consider, it may be difficult to directly apply this value all the
time. The value is approximate and other parameters,
such as alternative modes of secondary cell kill, could
cause deviations in this value. There is a room to further
investigate this in the future.The studies mentioned were
done with human fibrosarcoma xenografts that grew in
the legs of mice up to 6–7 mm in diameter and irradiated with single fractions, where some brain mets are
larger in size.25–31 Therefore, it must be recognized that
this is a simulation study, therefore, the results reported
are not predictive of current patient treatment. Further
clinical studies are warranted.
However, future research includes incorporating this
ICK approach for SIMT-VMAT plans in the treatment of
m-bm for reporting and clinical follow-up of the patient’s
tumor local control and treatment-related toxicity. It is
also important to further investigate the radiobiological
models of single-fraction SRS treatments in terms of
predicting tumor control probability (TCP) and how residual patient setup errors could affect the predicted treatment outcomes. Efforts have been made to model the
TCP for single fraction treatments, but many still present
with problems associated with unreliability of the current
LQ model for single high dose of SRS that was historically generated for fractionated radiotherapy.52 Therefore, TCP depends on clinical observations rather than
predicting local control rates. Tumor control can be further modeled with the relation of initial clonogenic cells
and survival with patient setup uncertainty and secondary cell death, in addition to the direct cell death.
It will also be useful to use cellular modeling to further
understand the magnitude of the damage made by DCK
versus ICK after single high dose of SRS treatment with
respect to reduced tumor cell kill for some given dose
levels as seen by tumor recurrences.

5

CONCLUSIONS

SRS treatment of m-bm using a SIMT-VMAT plan will
result in dosimetric discrepancies due to immitigable
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residual patient positioning uncertainties. In addition
to DCK, the ICK due to the vascular damage and/or
enhanced intratumor immune response with a single
high-dose of 15 Gy or higher tumor coverage could
potentially compensate for patient setup errors up to
±1.3 mm/1.3◦ in all six directions. It could still present
positive clinical outcomes for the tumor local control
along with no clinically significant increases in normal
brain toxicity. Clinical follow-up results of the m-bm
patients treated via a SIMT-VMAT SRS plan as a function of residual patient setup errors that incorporate ICK
in addition to DCK is warranted.
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